Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study in Hemodialysis Participants With Anemia of Chronic Kidney Disease to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Recombinant Human Erythropoietin or Its Analogs
Brief Summary: This Phase 3 study in hemodialysis-dependent subjects with anemia will evaluate the efficacy and safety of daprodustat administered three-times weekly compared to epoetin alfa, the current standard of care. This study includes a 4 week Screening Period, a 52 week Treatment Period and a 4 to 6 week follow-up period. Each subject will remain in the study for up to 62 weeks. Approximately 402 subjects will be randomized to receive either daprodustat three times weekly or epoetin alfa three-times weekly or once weekly, depending on dose level.


Options:
A: Arm Label: Daprodustat; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat small, Drug: Daprodustat large, Drug: Darbepoetin alfa placebo | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daprodustat small placebo, Drug: Daprodustat large placebo, Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Daprodustat small; Assigned to Arm(s): Daprodustat | Intervention Type: DRUG; Name: Daprodustat small placebo; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Daprodustat large; Assigned to Arm(s): Daprodustat | Intervention Type: DRUG; Name: Daprodustat large placebo; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa placebo; Assigned to Arm(s): Daprodustat
B: Arm Label: Daprodustat treated anemic subjects; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat, Drug: Iron therapy | Arm Label: Darbepoetin alfa treated anemic subjects; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa, Drug: Iron therapy | Intervention Type: DRUG; Name: Daprodustat; Assigned to Arm(s): Daprodustat treated anemic subjects | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa treated anemic subjects | Intervention Type: DRUG; Name: Iron therapy; Assigned to Arm(s): Daprodustat treated anemic subjects, Darbepoetin alfa treated anemic subjects
C: Arm Label: Molidustat (BAY 85-3934)(25mg); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY 85-3934) | Arm Label: Molidustat (BAY 85-3934)(50mg); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY 85-3934) | Arm Label: Molidustat (BAY 85-3934) (75mg); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY 85-3934) | Arm Label: Molidustat (BAY 85-3934) (150mg); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY 85-3934) | Arm Label: Epoetin alfa/beta; Type: ACTIVE_COMPARATOR; Interventions: Biological: Epoetin alfa/beta | Intervention Type: DRUG; Name: Molidustat (BAY 85-3934); Assigned to Arm(s): Molidustat (BAY 85-3934) (150mg), Molidustat (BAY 85-3934) (75mg), Molidustat (BAY 85-3934)(25mg), Molidustat (BAY 85-3934)(50mg) | Intervention Type: BIOLOGICAL; Name: Epoetin alfa/beta; Assigned to Arm(s): Epoetin alfa/beta
D: Arm Label: Daprodustat; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat tablets, Drug: Saline vials or bags | Arm Label: Epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Matching placebo tablets, Drug: Epoetin alfa vials | Intervention Type: DRUG; Name: Daprodustat tablets; Assigned to Arm(s): Daprodustat | Intervention Type: DRUG; Name: Matching placebo tablets; Assigned to Arm(s): Epoetin alfa | Intervention Type: DRUG; Name: Epoetin alfa vials; Assigned to Arm(s): Epoetin alfa | Intervention Type: DRUG; Name: Saline vials or bags; Assigned to Arm(s): Daprodustat

Answer: D